Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability

THOMSON REUTERS
15 Apr

Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10